Summary of Zomedica (ZOM) Conference Call - August 07, 2025 Company Overview - **Company**: Zomedica Corporation - **Ticker Symbol**: ZOMDF (OTCQB Venture Market) - **Industry**: Animal Health and Veterinary Services Key Points and Arguments 1. **Market Opportunity**: The total addressable market for Zomedica exceeds $2.7 billion annually, with the veterinary services segment in the U.S. valued at over $62 billion and growing [4][6]. 2. **Revenue Growth**: Zomedica has reported an increase in year-over-year revenues for 18 consecutive quarters, with revenues rising from $1 million in 2020 to $27 million in the last year [27][28]. 3. **Product Portfolio**: The company has developed six proprietary technology platforms aimed at improving veterinary care and practice profitability [4][5]. 4. **Capital and Liquidity**: Zomedica has $59 million in capital to support growth towards profitability [5][28]. 5. **High Margins**: The company maintains gross margins between 67% to 70%, with a focus on manufacturing its products to control costs [28][34]. 6. **Recurring Revenue Model**: A significant portion of revenue comes from consumable products, with nearly 70% of revenue from the PulseVet system derived from reorders of handpieces [13][14]. 7. **Innovative Technologies**: Key products include: - **PulseVet**: A shockwave therapy system generating significant revenue [10][11]. - **Assisi Loop**: A targeted pulse electromagnetic field therapy device, contributing about one-third of revenue from reorders [17][18]. - **Vetagel Hemostatic Gel**: A fast-acting gel for stopping bleeding, licensed for distribution in the U.S. [19][20]. - **TrueView Microscope**: A digital microscopy platform with AI capabilities, enhancing diagnostic capabilities for veterinarians [21][50]. - **TruForm Platform**: A diagnostic device utilizing bulk acoustic wave sensors, showing over 75% growth this year [22][23]. - **VetGuardian**: A pet monitoring device that provides vital signs without attachments, enhancing post-surgery care [24][25]. 8. **International Expansion**: Approximately 20% of revenue comes from international markets, with a 13% growth in international sales last quarter [30]. 9. **Future Growth Strategy**: Focus on leveraging commercial infrastructure, expanding product portfolio, and pursuing M&A opportunities while maintaining high margins [29][33]. 10. **Market Positioning**: The company believes it is undervalued, with a negative enterprise value despite significant revenue growth and potential [46][47]. Additional Important Insights - **COVID-19 Impact**: The pandemic led to an increase of 23 million pets in households, expanding the market for veterinary services [7]. - **Veterinary Challenges**: Veterinarians face staffing shortages and revenue loss to online competitors, which Zomedica aims to address with its products [9]. - **Economic Model**: The economic model for veterinarians using Zomedica's products is favorable, allowing them to achieve profitability quickly [15][16]. - **R&D and M&A Balance**: The company is shifting focus from R&D to scaling commercial adoption while still considering M&A opportunities for growth [39][40]. - **Future Product Launches**: New product launches are expected to enhance revenue and market presence, with AI integration in diagnostic tools [50][51]. This summary encapsulates the key insights from the Zomedica conference call, highlighting the company's market position, growth strategies, and innovative product offerings in the veterinary sector.

EX-99.1 2 zom_ex991.htm PRESS RELEASE EXHIBIT 99.1 Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth Zomedica posts record year-over-year revenue for 18 th straight quarter! ANN ARBOR, MI / ACCESSWIRE / August 6, 2025 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, tod ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-38298 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada N/A (St ...

ANN ARBOR, Mich., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive Officer, will present live at the OTCQB Venture Virtual Investor Conference hosted by VirtualInvestorConferences.com, on August 7th, 2025 DATE: August 7th TIME: 1:30 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: August 7– ...

Q3 2024 Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or in the territories or possessions thereof. Prospective investors should not construe the contents of this presentation as legal, tax, financial, investment or other advice. Each investor should make thei ...

Company Performance - Zomedica Corp. reported a quarterly loss of $0.02 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.01, marking an earnings surprise of -100% [1] - The company posted revenues of $6.5 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 16.45%, compared to revenues of $6.26 million a year ago [2] - Zomedica has not surpassed consensus EPS estimates over the last four quarters [2] Stock Movement and Outlook - Zomedica shares have declined approximately 51.6% since the beginning of the year, while the S&P 500 has gained 0.2% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for stock performance [4] - The current consensus EPS estimate for the coming quarter is -$0.01 on revenues of $8.49 million, and -$0.03 on revenues of $35.16 million for the current fiscal year [7] Industry Context - The Medical - Instruments industry, to which Zomedica belongs, is currently in the top 34% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Zomedica's stock performance [5]

Zomedica (ZOM) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jason Westphal - Sr. Director - FP&A, Reporting and M&ALarry Heaton - CEO & DirectorMike Zuehlke - Vice President of Finance & Corporate Controller Operator call is being recorded on Thursday, 05/15/2025. I would now like to turn the conference over to Jason Westfall, Senior Director, FP and A. Please go ahead. Jason Westphal Thank you, operator, and good afternoon, ladies and gentlemen. Welcome to Zometika's first quarter tw ...

Zomedica (ZOM) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 call is being recorded on Thursday, 05/15/2025. I would now like to turn the conference over to Jason Westfall, Senior Director, FP and A. Please go ahead. Speaker1 Thank you, operator, and good afternoon, ladies and gentlemen. Welcome to Zometika's first quarter twenty twenty five earnings results and business update call. Joining me on today's call are Zometika's Chief Executive Officer, Larry Heaton and Mike Zocke, our Vice President ...

[Management Commentary](index=1&type=section&id=Management%20Commentary) The CEO highlighted a record first quarter, marking the 17th consecutive quarter of year-over-year revenue growth, driven by strong consumable usage, increased international sales, and new product line introduction - Achieved record year-over-year revenue for the 17th consecutive quarter, delivering the strongest first quarter in company history[2](index=2&type=chunk) - International sales increased by **32%** compared to Q1 2024, driven by organic growth and new distributor partnerships[4](index=4&type=chunk) - Gross margin improved to **68%** in Q1 2025, compared to 66% in Q1 2024[4](index=4&type=chunk) - The company expanded its portfolio with the introduction of the new VETIGEL® product line to support future recurring sales revenue[3](index=3&type=chunk) [Financial Performance](index=1&type=section&id=Financial%20Performance) Zomedica's Q1 2025 revenue grew 4% year-over-year to $6.5 million, but a GAAP net loss of $63.8 million was recorded due to a significant non-cash impairment charge [Revenue Analysis](index=1&type=section&id=Revenue%20Analysis) Total revenue for Q1 2025 increased by 4% to $6.5 million, led by a 13% rise in Consumables and an 8% increase in Therapeutics, despite a 25% decline in Diagnostics Q1 2025 Revenue Breakdown vs. Q1 2024 | Category | Revenue (Q1 2025) | YoY Change | Note | | :--- | :--- | :--- | :--- | | **Total Revenue** | **$6.5 million** | **+4%** | 17th straight quarter of YoY growth | | Consumables | $4.5 million | +13% | Driven by TRUFORMA and PulseVet reorders | | Capital | $2.0 million | -12% | Impacted by non-recurring large orders in Q1 2024 | | **By Segment** | | | | | Therapeutics | $5.9 million | +8% | PulseVet® and Assisi® products | | Diagnostics | $0.6 million | -25% | Due to non-repeating large VetGuardian orders in Q1 2024 | [Profitability and Expenses](index=2&type=section&id=Profitability%20and%20Expenses) Gross margin for Q1 2025 was strong at 68%, with total operating expenses of $69.0 million heavily influenced by a $55.8 million non-cash impairment charge - A non-cash impairment charge of **$55.8 million** was recorded, triggered by the decline in the Company's market capitalization[11](index=11&type=chunk) Operating Expenses (Q1 2025 vs Q1 2024) | Expense Category | Q1 2025 | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | | Adjusted Operating Expenses* | $13.2 million | -9% | Lower G&A costs | | Research & Development | $1.9 million | +5% | Buildup of internal development capabilities | | Selling & Marketing | $5.0 million | +22% | Increased sales department headcount | | General & Administrative | $6.3 million | -27% | Non-recurrence of specialized professional fees | [Net Loss and EBITDA](index=2&type=section&id=Net%20Loss%20and%20EBITDA) The company reported a GAAP net loss of $63.8 million for Q1 2025, significantly higher than the prior year, primarily due to a $55.8 million impairment charge Profitability Metrics (Q1 2025 vs Q1 2024) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Loss (GAAP) | $(63.8) million | $(9.2) million | | Non-GAAP EBITDA Loss | $(61.7) million | $(7.5) million | | **Adjusted Non-GAAP EBITDA Loss** | **$(5.7) million** | **$(5.3) million** | [Liquidity and Outstanding Share Capital](index=2&type=section&id=Liquidity%20and%20Outstanding%20Share%20Capital) As of March 31, 2025, Zomedica maintained a solid liquidity position with $64.6 million in cash, cash equivalents, and available-for-sale securities, with approximately 980 million common shares outstanding - The company held **$64.6 million** in cash, cash equivalents, and available-for-sale securities as of March 31, 2025, compared to $71.4 million at the end of 2024[18](index=18&type=chunk) - As of March 31, 2025, there were **979,949,668** common shares issued and outstanding[18](index=18&type=chunk) [Conference Call Information](index=2&type=section&id=Conference%20Call%20Information) Zomedica scheduled a conference call and webcast for 4:30 p.m. ET on May 15, 2025, to review its first-quarter 2025 financial and operational results, with a replay accessible until May 29, 2025 - A conference call to discuss Q1 2025 financial results was scheduled for Thursday, May 15, 2025, at 4:30 p.m. Eastern Time[20](index=20&type=chunk) - A dial-in replay of the conference call will be available until May 29, 2025, using replay pin number 1148151[21](index=21&type=chunk) [Non-GAAP Financial Measures](index=4&type=section&id=Non-GAAP%20Financial%20Measures) This section defines the non-GAAP measures used by the company, such as Non-GAAP EBITDA and Adjusted Non-GAAP EBITDA, and provides a detailed reconciliation table - The company uses non-GAAP measures to evaluate operating performance; Adjusted Non-GAAP EBITDA excludes impairment charges and other non-recurring items from Non-GAAP EBITDA[30](index=30&type=chunk)[31](index=31&type=chunk) Reconciliation of Net Loss to Adjusted Non-GAAP EBITDA Loss | Line Item | Three Months Ended March 31, 2025 (in thousands) | | :--- | :--- | | Net loss and comprehensive loss | $(63,765) | | Impairment expense | $55,833 | | Amortization expense | $1,692 | | Depreciation expense | $521 | | Stock-compensation expense | $618 | | Interest income | $(730) | | Proforma adjustments | $143 | | **Adjusted Non-GAAP EBITDA loss** | **$(5,745)** |

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-38298 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada N/A (S ...